Table 2.
Selected studies evaluating extracorporeal photopheresis in chronic graft-versus-host disease.
| Author (Reference) | Sample Size | Study Type | Underlying Hematologic Conditions | ORR | CR | cGVHD Organ Specific Response rate | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Skin | Mucosa | Liver | GI | Ocular | Lung | ||||||
| Prospective Studies | |||||||||||
| Flowers et al. [21] | 48 | Phase II RCT | AML, ALL, CML, NHL, and others | 40% | 53% | 29% | 30% | ||||
| Greinix et al. [22] | 29 | Open-label crossover ECP study | AL, CL, HL, MDS | 31% | 31% | 70% | 50% | 60% | 27% | 57% | |
| Foss et al. [23] | 25 | Prospective | CML, NHL, CLL, AML, ALL | 64% | 64% | 80% | 24% | 46% | |||
| Seaton et al. [24] | 28 | Prospective | AML, ALL, MM, CML | 53% | 50% | ||||||
| Retrospective Studies | |||||||||||
| Couriel et al. [26] | 71 | Retrospective | ALL, AML/MDS, CLL, CML, MPD, lymphoma, AA, SCA, breast cancer | 61% | 20% | 57% | 78% | 71% | 67% | 54% | |
| Dignan et al. [27] | 82 | Retrospective | AL, MDS, HL, NHL, CLL, CML, MM | 79% | 7% | 100% | 91% | ||||
| Del Fante et al. [28] | 102 | Retrospective | HL, AML, ALL, CLL, CML, NHL, MM, MDS, PNH | 81% | 16% | ||||||
| Systematic Reviews | |||||||||||
| Abu-Dalle et al. [14] | 87 patients (5 studies), pooled results |
Systematic review | AL, AA, MDS, Thalassemia major, MM, CML, CLL, NHL, Fanconi’s anemia, solid tumor | 64% | 26% | 71% | 63% | 58% | 62% | 15% | |
| Malik et al. [29] | 595 patients (18 studies), pooled results |
Systematic review/ meta-analysis |
Various diseases | 64% | 29% | 74% | 72% | 68% | 53% | 60% | 48% |
| Consensus Statements | |||||||||||
| Pierelli et al. [17] | 735 patients (23 studies) |
Consensus statements | Various diseases | 64% | 47–57% | 27% | 57% | ||||
| Scarisbrick et al. [30] | 521 (23 studies) | Consensus statements | Various diseases | Mean 68% | Mean 63% | Mean 63% | |||||
| Alfred et al. [19] | 725 (27 studies) | Consensus statements | Various diseases | Mean 68% | Mean 74% | Mean 62% | Mean 62% | Mean 46% | Mean 60% | Mean 46% | |
ORR: overall response rate; CR: complete response; PR: partial response; cGVHD: chronic graft-versus-host disease; RCT: randomized controlled trial; HL: Hodgkin’s lymphoma; GI: gastrointestinal; AML: acute myeloid leukemia; ALL: acute lymphoblastic leukemia; CLL: chronic lymphocytic leukemia; CML: chronic myelogenous leukemia; NHL: Non-Hodgkin’s lymphoma; MM: multiple myeloma; AA: aplastic anemia; ARDS: adult respiratory distress syndrome; ECP: extracorporeal photopheresis; AL: acute leukemia; MDS: myelodysplastic syndrome; MPD: myeloproliferative disease; SCA: sickle cell anemia; PNH, paroxysmal nocturnal hemoglobinuria.